Surgical robots

FDA clears Medtronic Hugo robot for general surgery, about 3.5 million U.S. procedures a year

The Medtronic Hugo robotic surgery system on a white background: a monitor cart, the open surgeon console with a large screen, a tower cart with a screen and equipment, and a wheeled robotic arm cart with an instrument arm raised.
The Hugo RAS system, including the open surgeon console and a modular arm cart (Medtronic image from the FDA clearance announcement).. Image: Image: Medtronic

Medtronic said on Nov. 17 that the FDA cleared its Hugo robotic-assisted surgery system for general surgery. The expanded 510(k) covers all upper abdominal general surgical procedures, including gallbladder removal (cholecystectomy), Roux-en-Y gastric bypass, ventral hernia and small bowel resection, plus inguinal hernia repair and appendectomy. Medtronic estimates those procedures account for about 3.5 million U.S. surgeries a year, more than half of all U.S. soft-tissue procedures. Hugo's U.S. label previously covered only urology, cleared in December 2025. FDA's 510(k) database lists the new clearance as K261444, received May 1, 2026 and decided Nov. 13, four days before the announcement. A separate gynecology application remains under FDA review, MassDevice reports. Medtronic says Hugo is on track to pass 50,000 cumulative procedures worldwide by the end of its fiscal year in April 2027, with about 250 installed systems expected, per MassDevice. Pricing was not disclosed.

Source: Medtronic via PR Newswire (Nov. 17, 2026): FDA clearance of general surgery procedures for the Hugo RAS system (procedures covered, about 3.5 million U.S. surgeries a year, growth more than 2x market, 50,000 procedures by fiscal year end)

Servospace take: Hugo now has the label to compete where da Vinci makes its volume, but it starts about 48 times smaller

Servospace analysis: general surgery is where U.S. robotic surgery volume is, and until this clearance Hugo could not compete for it in the U.S. The gap is still enormous. Intuitive Surgical reported 12,094 da Vinci systems installed worldwide as of Sept. 30, 2026, 6,807 of them in the United States, and about 906,000 da Vinci procedures in the third quarter of 2026 alone. Medtronic's own targets, about 250 installed Hugo systems and 50,000 cumulative procedures by April 2027, put Hugo's installed base at roughly 1/48th of da Vinci's worldwide and its lifetime procedure count at about 1/18th of a single quarter of da Vinci cases (Servospace arithmetic on company figures). Medtronic's pitch is not raw scale but fit: a modular design that lets teams use only the robotic arms a case needs, an open console, and familiar Medtronic instruments such as the LigaSure RAS Maryland vessel sealer. The FDA timeline matters too: 196 days from receipt to decision for this filing, versus 268 days for Hugo's first U.S. clearance (received March 10, decided Dec. 3, 2025), per FDA 510(k) records. Watch for U.S. hospital placements and pricing, neither disclosed, and the pending gynecology decision.

Get stories like this weekly.

Watch new robot Shorts every day on YouTube →